Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 1, 1998, Pages 307-311

  Domino, Edward F ^a   Ni, Lisong ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MUSCARINIC M1 RECEPTOR ANTAGONIST; ROTIGOTINE; TRIHEXYPHENIDYL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; BENZAZEPINES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; MACACA NEMESTRINA; MPTP POISONING; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TETRAHYDRONAPHTHALENES; THIOPHENES; TRIHEXYPHENIDYL;

EID: 0031886770     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM and Kopin IJ (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 39: 7-16.
2. 2 receptor agonist: Is it efficacious in rat and monkey models of Parkinson's disease? Movement Dis 2:147-154.
3. 2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J Neurochem 54:2145-2148.
4. Consolo S, Wu CF and Fusi R (1987) D-1 receptor-linked mechanism modulates cholinergic neurotransmission in rat striatum. J Pharmacol Exp Ther 242:300-305.
5. 1-dependent control of in vivo acetylcholine release in rat striatum. Neuroscience 71:157-165.
6. Damsma G, DeBoer P, Westerink BHC and Fibiger HC (1990) Dopaminergic regulation of striatal cholinergic interneurons: An in vivo microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 342:523-527.
7. 1 and NMDA receptors. J Pharmacol Exp Ther 259:1064-1072.
8. 2 dopamine receptor subtypes. J Pharmacol Exp Ther 277:775-783.
9. DeBoer P, Damsma G, Schram Q, Stoof JC, Zaagsma J and Westerink BHC (1992) The effect of intrastriatal application of directly and indirectly acting dopamine agonist and antagonists on the in vivo release of acetylcholine measured by brain microdialysis. Naunyn-Schmiedeberg's Arch Pharmacol 345:144-152.
10. 2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 164:221-225.
11. 2 receptor in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 165:1387-1391.
12. Domino EF, Ni L, Zhang H, Kohno Y and Sasa M (1997) Talipexole or pramipexole combinations with chloro-APT (SKF-82958) in MPTP induced hemiparkinsonian monkeys. Eur J Pharmacol 325:137-144.
13. 2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion. Neuroscience 54:1051-1061.
14. Fage D and Scatton B (1986) Opposing effects of D-1 and D-2 receptor antagonists on acetylcholine levels in the rat striatum. Eur J Pharmacol 129:359-362.
15. Fassio A, Bonanno G, Fontana G, Usai C, Marchi M and Raiteri M (1996) Role of external and internal calcium on heterocarrier-mediated transmitter release. J Neurochem 66:1468-1474.
16. 1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol 89:83-90.
17. 3H] acetylcholine release from rat striatal slices. Gen Pharmacol 27: 1203-1207.
18. Johnson BJ and Bruno JP (1995) Dopaminergic modulation of striatal acetylcholine release in rats depleted of dopamine as neonates. Neuropharmacology 34:191-203.
19. Koshikawa N, Yoshida Y, Kitamura M, Saigusa T, Kobayashi M and Cools AR (1996) Stimulation of acetylcholine or dopamine receptors in the nucleus accumbens differentially alters dopamine release in the striatum of freely moving rats. Eur J Pharmacol 303:13-19.
20. Lehmann J and Langer SZ (1983) The striatal cholinergic interneuron: synaptic target of dopaminergic terminals? Neuroscience 10:1105-1120.
21. 1 DA receptor-mediated control of striatal acetylcholine release in vitro. Brain Res 681:209-212.
22. 1 dopamine agonist stimulates acetylcholine release from dissociated striatal cholinergic neurons. Brain Res 727:162-168.
23. 2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 182:611-612.
24. 2-mediated behavior in the 6-hydroxydopamine model of turning: Relationship with c-fos expression. J Pharmacol Exp Ther 260:402-408.
25. Olney JW, Price MT, Labruyere J, Salles KS, Frierdich G, Mueller M and Silverman E (1987) Anti-parkinsonian agents are phencyclidine agonists and N-methyl-D-aspartate antagonists. Eur J Pharmacol 142:319-320.
26. 1 agonist-induced turning in mice. Neurosci Lett 205: 185-188.
27. Pycock C, Milson J, Tarsy D and Marsden CD (1978) The effect of manipulation of cholinergic mechanisms on turning behaviour in mice with unilateral destruction of the nigro-neostriatal dopaminergic system. Neural Pharmacol 17:175-183.
28. 2 receptor agonists on striatal acetylcholine release. Eur J Pharmacol 219:323-325.
29. Robertson GS, Tham C-S, Wilson C, Jakubovic A and Fibiger HC (1993) In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 264:1344-1351.
30. 3 agonist, on acetylcholine release during striatal microdialysis in conscious rats. Brain Res 655:233-236.
31. Scatton B (1982) Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: Evidence against dopamine receptor multiplicity. J Pharmacol Exp Ther 220:197-202.
32. Steinberg R, Rodier D, Souilhac J, Bougault I, Emonds-Alt X, Soubrie P and Le Fur G (1995) Pharmacological characterization of tachykinin receptors controlling acetylcholine release from rat striatum: An in vivo microdialysis study. J Neurochem 65:2543-2548.
33. Stoof JC, Thieme RE, Vrijmoed-de Vries MC and Mulder AH (1979) In vitro acetylcholine release from the rat caudate nucleus as a new model for testing drugs with dopamine-receptor activity. Naunyn-Schmiedeberg's Arch Pharmacol 309:119-124.
34. +-stimulated release of acetylcholine from rat neostriatum. Brain Res 250: 263-270.
35. Stoof JC, Drukarch B, de Boer P, Westerink BHC and Groenewegen JH (1992) Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience 47:755-770.
36. Tien X-Y and Wallace LJ (1985) Trihexyphenidyl: Further evidence for muscarinic receptor subclassification. Biochem Pharmacol 34:588-590.
37. Ueda H, Sato K, Okumura F and Misu Y (1995) L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats. Brain Res 698:213-216.
38. Ungerstedt U (1974) Brain dopamine neurons and behavior, in The Neurosciences Third Study Program (Schmitt FO and Worden FG, eds) pp 695-703, The MIT Press, Cambridge, MA.
39. Weinstock J, Wilson JW, Ladd DL, Brush CK, Pfeiffer FR, Kuo GY, Holden KG, Yim NCF, Han RA, Wardell JR, Tobia AJ, Setler PE, Sarau HM and Ridley PT (1980) Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines. J Med Chem 23:973-975.